Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2025; 17(2): 102342
Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.102342
Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness
Chun-Chun Yang, Sui Zhang, Rui Zhang, Ya-Nan Zhao, Da-Wei Yang, Ming-Yue Yang, Li-Jing Huang
Chun-Chun Yang, Department of Gastroenterology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Sui Zhang, Da-Wei Yang, Department of Hepatic, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Rui Zhang, Ya-Nan Zhao, Ming-Yue Yang, Department of Gastroenterology Center, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Li-Jing Huang, Department of Rheumatology and Immunology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Co-first authors: Chun-Chun Yang and Sui Zhang.
Co-corresponding authors: Ming-Yue Yang and Li-Jing Huang.
Author contributions: Yang CC, Zhang S, and Zhang R designed the research study; Yang CC and Zhang S contributed equally to this article, they are the co-first authors of this manuscript; Zhao YN, Yang DW performed the research; Yang MY and Huang LJ conducted experiments, analyzed the data, they contributed equally to this article, they are the co- corresponding authors of this manuscript; Yang CC, Zhang S, Zhang R, Zhao YN, Yang DW, Yang MY, and Huang LJ contributed to editorial changes in the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the First Hospital of Hebei Medical University, approval No. 25153323.
Informed consent statement: Informed consent was obtained from all study participants.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Yue Yang, Department of Gastroenterology Center, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang 050000, Hebei Province, China. mijing74024651@163.com
Received: November 7, 2024
Revised: December 7, 2024
Accepted: December 26, 2024
Published online: February 27, 2025
Processing time: 76 Days and 2 Hours
Core Tip

Core Tip: The application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness. Compared to sole sulfasalazine intervention, the combined application of Saccharomyces boulardii further promotes the relief of relevant symptoms in patients, alleviates intestinal mucosal inflammation, and improves the quality of life. Its action may be related to rectifying the imbalance in intestinal microbiota and improving intestinal mucosal barrier function. Moreover, the combined use of Saccharomyces boulardii does not increase the risk of adverse reactions in patients, indicating a higher level of medication safety and advocating for its clinical promotion and application.